日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

Chinese researchers publish major clinical study on ovarian cancer

By Li Jing | chinadaily.com.cn | Updated: 2025-12-15 17:37
Share
Share - WeChat

A major Chinese clinical study on ovarian cancer has been published in CA: A Cancer Journal for Clinicians, one of the world's highest-impact medical journal, marking a first for a Chinese researcher-led gynecological cancer trial, researchers said in Beijing on Sunday.

The phase III FZOCUS-1 study tested fluzoparib, a PARP inhibitor developed by Chinese pharmaceutical giant Hengrui Pharma. The trial evaluated the drug as a "maintenance" therapy, treatment given to prevent cancer recurrence after initial chemotherapy for advanced ovarian cancer, either alone or in combination with the targeted drug apatinib.

Conducted over six years at 54 hospitals across China, the randomized, double-blind trial enrolled 674 patients. Results showed that fluzoparib-based maintenance therapy significantly delayed disease progression compared with a placebo.

In the overall study population, patients receiving fluzoparib alone achieved a median progression-free survival of 29.9 months, the research team said.

The results were even more striking for patients with BRCA mutations. In this group, median progression-free survival reached 47.8 months, nearly three times that of the placebo group.

The study also found that patients with a specific generic marker of homologous recombination deficiency could benefit from fluzoparib alone, potentially allowing them to avoid the side effects and extra costs associated with combination therapy. Meanwhile, patients without this generic marker, who typically face poorer outcomes, showed encouraging results from the combination therapy of fluzoparib and apatinib.

"Ovarian cancer is often diagnosed late and remains difficult to treat," Wu Lingying, the study's principal investigator from the Cancer Hospital of the Chinese Academy of Medical Sciences, said.

"This research, designed and completed entirely by Chinese teams, provides solid evidence that can help improve treatment decisions both in China and globally."

Ovarian cancer causes about 200,000 deaths worldwide each year. In China, around 61,000 women are diagnosed annually, with roughly 38,000 deaths, according to the research team.

Wang Quanren, vice-president of Hengrui Pharma, said the high-profile publication highlights the growing impact of China's drug innovation. He added that fluzoparib has been included in China's national medical insurance program since 2021, making the treatment more accessible to patients.

Researchers said the findings offer new, practical guidance for precision treatment of advanced ovarian cancer and underscore China's expanding role in global clinical research.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 你懂的在线视频 | 五月婷婷色 | 中文字幕有码在线 | 韩日黄色片 | 日韩在线观看不卡 | 久久久久 | 精品久久久在线观看 | 亚洲天堂手机在线 | 黄色免费在线观看网站 | 欧美日韩在线免费视频 | 99re视频这里只有精品 | 美女啪啪网站 | 国产精品综合网 | 国产九色在线 | 色婷婷av一区二区 | 日韩精品视频网站 | 国产激情在线 | 欧美成人手机在线 | 免费av成人 | 欧美亚洲综合在线 | 色花av | 亚洲精品综合 | 亚洲在线免费观看视频 | 久久黄视频 | 中文字幕偷拍 | 久久99精品久久久久久国产越南 | 国产高潮呻吟久久久 | 久久久91视频 | 免费中文字幕视频 | 国产视频在线观看一区二区 | 久久久精品视频在线观看 | 欧美草草| 亚洲成人精品视频 | 久久99国产精品 | 青青视频国产 | 欧美一区二区三区四 | 国产又大又黄 | 国产黄色免费网站 | 国产主播精品 | 在线观看国产欧美 | 色福利视频 |